Akari Therapeutics (AKTX) Cash & Equivalents (2011 - 2026)

Akari Therapeutics (AKTX) has 15 years of Cash & Equivalents data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 7.04% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 7.04% YoY), and the FY2025 full-year result was $5.2 million, up 95.68% from the prior year.
• Cash & Equivalents eased to $2.8 million in Q1 2026, from $5.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.2 million in Q4 2022 to a low of $162567.0 in Q3 2025.
• A 5-year average of $3.7 million and a median of $2.8 million in 2025 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 101.68% in 2025, while the deepest fall reached 92.76% in 2025.
• Tracing AKTX's Cash & Equivalents over 5 years: stood at $13.2 million in 2022, then plunged by 70.98% to $3.8 million in 2023, then tumbled by 30.85% to $2.7 million in 2024, then soared by 95.68% to $5.2 million in 2025, then slumped by 45.65% to $2.8 million in 2026.
• Business Quant data shows AKTX's Cash & Equivalents at $2.8 million in Q1 2026, $5.2 million in Q4 2025, and $162567.0 in Q3 2025.